How to buy Bristol-Myers Squibb (BMY) shares in the UK

Learn how to easily invest in Bristol-Myers Squibb shares.

Bristol-Myers Squibb Company (BMY) is a publicly traded drug manufacturers-general business based in the US. It opened the day at $70.63 after a previous close of $71.21. During the day the price has varied from a low of $70.665 to a high of $71.795. The latest price was $71.45 (25 minute delay). Bristol-Myers Squibb is listed on the NYSE and employs 32,200 staff. All prices are listed in US Dollars.

How to buy shares in Bristol-Myers Squibb

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BMY in this case.
  5. Research Bristol-Myers Squibb shares. The platform should provide the latest information available.
  6. Buy your Bristol-Myers Squibb shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 10x Bristol-Myers Squibb shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £3.15
£632.19 total
Capital at risk
IG Share Dealing logo £0 £250 £11.99
£641.04 total
Capital at risk
Fineco logo £0 No minimum £6.29
£635.34 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £18.24
£647.29 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.63
£629.67 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £17.43
£646.47 total
Capital at risk
Stake logo £0 £50 £3.15
£632.19 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £17.36
£646.41 total
Capital at risk

Full comparison of share dealing platforms

Bristol-Myers Squibb share price (NYSE:BMY)

Use our graph to track the performance of BMY stocks over time.

Bristol-Myers Squibb price performance over time

Historical closes compared with the last close of $71.45

1 week (2022-09-29) -0.36%
1 month (2022-09-06) 4.08%
3 months (2022-07-06) -6.26%
1 year (2021-10-06) 20.71%
2 years (2020-10-06) 23.74%
3 years (2019-10-04) 40.79%
5 years (2017-10-06) 10.25%

Is it a good time to buy Bristol-Myers Squibb stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.

Promoted
eToro Free Stocks

Invest in Bristol-Myers Squibb shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is Bristol-Myers Squibb under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Bristol-Myers Squibb's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Bristol-Myers Squibb shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Bristol-Myers Squibb's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.

PEG ratio

Bristol-Myers Squibb's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4369. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Bristol-Myers Squibb's PEG ratio in relation to those of similar companies.

EBITDA

Bristol-Myers Squibb's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $21.1 billion (£18.6 billion).

The EBITDA is a measure of a Bristol-Myers Squibb's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb.

Total ESG risk score

Bristol-Myers Squibb's total ESG risk: 29.16

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb's overall score of 29.16 (as at 01/01/2019) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Bristol-Myers Squibb's total ESG risk score against those of similar companies.

Environmental score

Bristol-Myers Squibb's environmental score: 3.83/100

Bristol-Myers Squibb's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Bristol-Myers Squibb's social score: 18.82/100

Bristol-Myers Squibb's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Bristol-Myers Squibb's governance score: 14.02/100

Bristol-Myers Squibb's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Bristol-Myers Squibb's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Bristol-Myers Squibb scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb has, for the most part, managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.

Total ESG score 29.16
Total ESG percentile 52.58
Environmental score 3.83
Environmental score percentile 4
Social score 18.82
Social score percentile 4
Governance score 14.02
Governance score percentile 4
Level of controversy 2

Bristol-Myers Squibb shares at a glance

Information last updated 2022-10-05.
Open$70.63
High$71.795
Low$70.665
Close$71.45
Previous close$71.21
Change$0.24
Change %0.337%
Volume6,760,104
Information last updated 2022-10-02.
52-week range$52.0099 - $80.0341
50-day moving average$71.911
200-day moving average$71.355
Wall St. target price$81.44
PE ratio23.6179
Dividend yield$2.11 (3.04%)
Earnings per share (TTM)$3.01

Bristol-Myers Squibb share dividends

3.0%

Dividend yield: 3.04% of stock value

3.0%

Forward annual dividend yield: 3.04% of stock value

28.0%

Dividend payout ratio: 27.98% of net profits

Bristol-Myers Squibb has recently paid out dividends equivalent to 3.04% of its share value annually.

Bristol-Myers Squibb has paid out, on average, around 27.98% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.04% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 3.04% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb's case, that would currently equate to about $2.11 per share.

While Bristol-Myers Squibb's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

Bristol-Myers Squibb's most recent dividend payout was on 1 November 2022. The latest dividend was paid out to all shareholders who bought their shares by 6 October 2022 (the "ex-dividend date").

Bristol-Myers Squibb's dividend yield is perhaps best considered in relation to those of similar companies.

Share price volatility

Over the last 12 months, Bristol-Myers Squibb's shares have ranged in value from as little as $52.0099 up to $80.0341. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb's is 0.4227. This would suggest that Bristol-Myers Squibb's shares are less volatile than average (for this exchange).

To put Bristol-Myers Squibb's beta into context you can compare it against those of similar companies.

Frequently asked questions

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site